MACK Merrimack Pharmaceuticals Inc.

10.82
+0.08  (1%)
Previous Close 10.74
Open 10.68
Price To book 1.29
Market Cap 144262703
Shares 13,332,967
Volume 93,274
Short Ratio 13.86
Av. Daily Volume 155,487

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2018.
MM-121 (SHERBOC)
HER2 negative metastatic breast cancer
Phase 2 completion of enrollment announced June 19, 2017. Data due 1H 2018.
MM-141 - CARRIE
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
ONIVYDE
Cancer - second line pancreatic
Phase 2 initiated mid Feb 2015. Data due 2H 2018.
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
ONIVYDE
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
ONIVYDE
Cancer - front line pancreatic

Latest News

  1. Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference
  2. New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
  3. Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference
  4. Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?
  5. Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
  6. With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Inc’s (MACK) Management Done A Good Job?
  7. Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
  8. Edited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMT
  9. Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
  10. Merrimack beats 3Q profit forecasts
  11. Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss
  12. Merrimack Reports Third Quarter 2017 Financial Results
  13. Merrimack Pharmaceuticals, Inc. to Host Earnings Call
  14. What's in the Cards for Merrimack (MACK) in Q3 Earnings?
  15. Featured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer
  16. Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call
  17. Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121
  18. NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers
  19. Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer
  20. Have Investors Already Priced In Merrimack Pharmaceuticals Inc’s (MACK) Growth?